PFE Stock Analysis: Pfizer | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 137.015m USD | 12M Return: 2.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.14B
EPS Trend: 23.8%
Qual. Beats: 0
Rev. Trend: -24.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pfizer Inc. is a New York-based global biopharmaceutical company founded in 1849, operating in three segments: Biopharma, PC1, and Pfizer Ignite. The pharmaceutical sector is characterized by long R&D cycles, heavy regulatory oversight, and reliance on patent-protected products, which typically drive a high-cost, high-margin business model.
The company markets a diversified portfolio spanning internal medicine, vaccines, inflammation and immunology, rare diseases, oncology, biosimilars, and sterile injectables. Major brands include Eliquis, Prevnar, Paxlovid, Xeljanz, Vyndaqel, Ibrance, and Xtandi. Pharma companies like Pfizer typically generate revenue from a mix of blockbuster patented therapies and, increasingly, lower-margin biosimilars as patents expire.
Pfizer maintains collaboration agreements with Bristol-Myers Squibb, Astellas Pharma, Merck KGaA, and BioNTech, as well as a strategic AI partnership with Boltz, PBC. Such alliances are common in the biopharma industry, where co-development and licensing agreements help share R&D risk and accelerate pipeline expansion across global markets.
- Paxlovid and Comirnaty revenue decline steepens post-pandemic
- Eliquis patent expiry threatens multi-billion dollar revenue base
- Seagen acquisition integration drives oncology segment growth
| Net Income: 7.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: 13.38% < 20% (prev 15.06%; Δ -1.68% < -1%) |
| CFO/TA 0.06 > 3% & CFO 12.0b > Net Income 7.49b |
| Net Debt (51.4b) to EBITDA (16.7b): 3.07 < 3 |
| Current Ratio: 1.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.73b) vs 12m ago 0.37% < -2% |
| Gross Margin: 69.35% > 18% (prev 66.93%; Δ 2.41% > 0.5%) |
| Asset Turnover: 30.47% > 50% (prev 30.03%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 3.94 > 6 (EBIT TTM 10.6b / Interest Expense TTM 2.69b) |
| A: 0.04 (Total Current Assets 42.8b - Total Current Liabilities 34.3b) / Total Assets 208b |
| B: 0.56 (Retained Earnings 117b / Total Assets 208b) |
| C: 0.05 (EBIT TTM 10.6b / Avg Total Assets 208b) |
| D: 0.77 (Book Value of Equity 90.1b / Total Liabilities 117b) |
| Altman-Z'' = 3.26 = A |
| DSRI: 0.84 (Receivables 12.6b/14.7b, Revenue 63.3b/62.5b) |
| GMI: 0.97 (GM 66.93% / 69.35%) |
| AQI: 1.01 (AQ_t 0.70 / AQ_t-1 0.69) |
| SGI: 1.01 (Revenue 63.3b / 62.5b) |
| TATA: -0.02 (NI 7.49b - CFO 12.0b) / TA 208b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 03, 2026, the stock is trading at USD 24.32 with a total of 51,809,215 shares traded. Over the past week, the price has changed by +2.75%, over one month by -4.81%, over three months by -12.71% and over the past year by +2.76%.
Current recommended Stop Loss: 23.50 (which is 3.4% or 1.4 ATR below the current price).
Pfizer has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold PFE.
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 29.2 | 19.9% |
P/E Trailing = 18.3511
P/E Forward = 8.0257
P/S = 2.1307
P/B = 1.4973
P/EG = 2.7668
Revenue TTM = 63.3b USD
EBIT TTM = 10.6b USD
EBITDA TTM = 16.7b USD
Long Term Debt = 59.8b USD (from longTermDebt, last quarter)
Short Term Debt = 3.89b USD (from shortTermDebt, last quarter)
Debt = 64.5b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 51.4b USD (calculated: Debt 64.5b - CCE 13.1b)
Enterprise Value = 188b USD (137b + Debt 64.5b - CCE 13.1b)
Interest Coverage Ratio = 3.94 (Ebit TTM 10.6b / Interest Expense TTM 2.69b)
EV/FCF = 19.86x (Enterprise Value 188b / FCF TTM 9.48b)
FCF Yield = 5.03% (FCF TTM 9.48b / Enterprise Value 188b)
FCF Margin = 14.98% (FCF TTM 9.48b / Revenue TTM 63.3b)
Net Margin = 11.83% (Net Income TTM 7.49b / Revenue TTM 63.3b)
Gross Margin = 69.35% ((Revenue TTM 63.3b - Cost of Revenue TTM 19.4b) / Revenue TTM)
Gross Margin QoQ = 67.26% (prev 69.97%)
Tobins Q-Ratio = 0.91 (Enterprise Value 188b / Total Assets 208b)
Interest Expense / Debt = 4.17% (Interest Expense 2.69b / Debt 64.5b)
Taxrate = 4.86% (384.0m / 7.91b)
NOPAT = 10.1b (EBIT 10.6b * (1 - 4.86%))
Current Ratio = 1.25 (Total Current Assets 42.8b / Total Current Liabilities 34.3b)
Debt / Equity = 0.72 (Debt 64.5b / totalStockholderEquity, last quarter 90.1b)
Debt / EBITDA = 3.07 (Net Debt 51.4b / EBITDA 16.7b)
Debt / FCF = 5.42 (Net Debt 51.4b / FCF TTM 9.48b)
Total Stockholder Equity = 89.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 7.49b / Total Assets 208b)
RoE = 8.37% (Net Income TTM 7.49b / Total Stockholder Equity 89.5b)
RoCE = 7.09% (EBIT 10.6b / Capital Employed (Equity 89.5b + L.T.Debt 59.8b))
RoIC = 5.79% (NOPAT 10.1b / Invested Capital 174b)
WACC = 6.34% (E(137b)/V(201b) * Re(7.46%) + D(64.5b)/V(201b) * Rd(4.17%) * (1-Tc(0.05)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 0.66%
[DCF] Terminal Value 73.10% ; FCFF base≈10.2b ; Y1≈8.93b ; Y5≈7.21b
[DCF] Fair Price = 11.30 (EV 116b - Net Debt 51.4b = Equity 64.4b / Shares 5.70b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 23.79 | EPS CAGR: 10.46% | SUE: 0.27 | # QB: 0
Revenue Correlation: -24.44 | Revenue CAGR: -2.41% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.85 | Chg30d=+0.08% | Revisions=+0% | Analysts=18
EPS current Year (2026-12-31): EPS=2.96 | Chg30d=-0.11% | Revisions=+13% | GrowthEPS=-8.1% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=2.83 | Chg30d=-0.29% | Revisions=+22% | GrowthEPS=-4.4% | GrowthRev=-3.8%
[Analyst] Revisions Ratio: +22%